Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

SciNeuro In-Licenses China Rights to Lilly Treatment for Parkinson's

publication date: Apr 14, 2021

Shanghai's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies, an expected therapy for Parkinson's. SciNeuro will make an upfront payment along with downstream milestones and royalties, though details were not disclosed. In December 2020, SciNeuro was launched with $100 million from Lilly Asia Ventures and Arch Venture Partners to develop CNS therapies for China. Min Li, PhD, a Venture Partner at Lilly Asia Ventures, is Founder and CEO of SciNeuro. The Lilly deal is SciNeuro's first in-licensing. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.